AstraZeneca’s Lynparza meets primary endpoint in late-stage ovarian cancer trial
AstraZeneca is competing with GSK to win the race to become the go-to maintenance treatment for people who have been treated for ovarian cancer
Sector
Health
988 stories · page 47 of 50
ReNeuron inks University of Cardiff collaboration
The venture will utilise ReNeuron's exosome-based drug delivery technology
Benchmark Holdings appoints Dechra Pharmaceutical director as CFO
Septima Maguire, who spent four years at Dechra Pharmaceuticals, will start her new role at Benchmark in November
Genprex boss Rodney Varner trumpets gene therapy company’s recent achievements
Varner said “we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research"
Biocept bolsters its intellectual property arsenal with three new patents
The patents cover its antibody and microchannel technology and the detection of cancer cells, which collectively is used to capture cells of interest in a biopsy
e-therapeutics teams up with a top-five pharma company for neurodegenerative diseases project
The 12-month tie-up with the unnamed drug giant will showcase the research group's network-driven drug discovery approach
VolitionRx balance sheet strengthens in second quarter with cash increasing significantly
The Belgium-based firm said its cash and cash equivalents as of June 30, 2019 totaled $18.5 million compared to $13.4 million as of the end of 2018
Biocept shares rise after reporting revenue boost in 2Q
The firm said growth was driven by a 26% year-over-year increase in commercial samples as it focused on segments of the liquid biopsy oncology market
Callitas Health capitalizes on CannaStrips, OTC goods while swinging for the fence with blockbuster drugs
Callitas Health Inc CEO James Thompson says the company has 'a lot of irons in the fire that should come to fruition over the next few months'
Orgenesis Inc sees record fiscal 2Q revenue beat estimates
The company saw its revenue shoot up by 95% to $7.8 million, which easily beat the consensus estimate of $6.4 million
NA Proactive news snapshot: Biocept, Orgenesis, Ipsidy, VolitionRx UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
ImmuPharma targets regulatory approval as follow-up study confirms “outstanding” safety profile of Lupuzor
The drug developer also recently raised £2.66mln from its institutional investor, Lanstead Capital, to help execute its corporate strategy
Propanc Biopharma publishes promising study of its metastatic cancer drug in peer-reviewed medical journal
The study confirmed the effects its drug against cancer stem cells within tumors that are capable of self-renewal and often resist chemotherapy
BevCanna Enterprises launches Grüv Beverages, a range of CBD-infused iced tea drinks
The new line will be available initially in the US and in Canada following the legalization of infused products in October 2019
Circassia brings in top Pfizer exec as new chief operating officer
Jonathan Emms, who will officially join in September, arrives at a time when Circassia is transitioning into a more commercially-focused business
Benchmark Holdings hopeful string of licensing deals will offset ‘challenging’ shrimp and seabass markets
“The company is actively progressing its programme of operational and structural efficiencies, including key commercial licensing deals for its non-core animal vaccines, which, if completed this financial year, are expected to substantially
OptiBiotix continues to see commercial traction for its functional food technology
The latest deal involving its weight management productcovers Australia and New Zealand
Nemaura Medical boosts cash position in 1Q to launch SugarBeat in UK and other key European markets
The medtech company has a cash pile of $3,068,541 and an influx of cash in the form of an $8 million senior credit facility from its investors
IPO Roundup: AMTD International, InMode LTD each find their footing after going public
The two international companies are both up since they started trading in New York this week
Acasti Pharma reiterated as Speculative Buy by Mackie after FDA setback news for competitor Amarin
Amarin had recently indicated that they did not think they would need an FDA adcom meeting for their sNDA (supplemental new drug application) for Vascepa